Carcinogenesis, Teratogenesis & Mutagenesis ›› 2015, Vol. 27 ›› Issue (2): 111-115.doi: 10.3969/j.issn.1004-616x.2015.02.007

Previous Articles     Next Articles

Effects of carboplatin combination with TRAIL on the proliferation and apoptosis of lung adenocarcinoma cancer cell line A549

WANG Huimin1, WANG Hongying1, DAI Suli2, LI Lei2, ZHAO Lianmei2   

  1. 1. Department of Respiratory Medicine, Chifeng Municipal Hospital, Chifeng 024300, Inner Mongolia;
    2. Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2014-09-10 Revised:2014-12-08 Online:2015-03-31 Published:2015-03-31
  • About author:10.3969/j.issn.1004-616x.2015.02.007

Abstract:

OBJECTIVE:To study the effects of carboplatin combined with TRAIL (TNF- related apoptosis inducing ligand) on proliferation and apoptosis of human lung cancer A549 cells. METHODS:After treated by TRAIL, carboplatin or combination of two drugs, the proliferation of A549 was measured by MTS and apoptosis rate was evaluated by flow cytometry. The morphology was investigated by microscopy. RT-PCR and Western blot were used to examine the gene and protein expressions of DR4, DR5, Survivin and XIAP. RESULTS:Carboplatin or TRAIL alone or combined inhibited the proliferation of A549 cells in concentration-dependent (20-80 μg/mL) manner. Carboplatin combined with TRAIL exhibited a stronger inhibitory effect and induced apoptosis than when used alone. Carboplatin could down-regulate the protein expression level of Survivin and XIAP and increase the DR5 protein expression level, but have no effect on DR4 expression. CONCLUSION:Combination of carboplatin and TRAIL could inhibit proliferation and apoptosis via influencing the expressions of Survivin, XIAP and DR5 in A549 cells.

Key words: carboplatin, TRAIL, A549, proliferation, apoptosis

CLC Number: